Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

N/A
3(100.0%)
3Total
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06718894Not ApplicableRecruiting

Multitarget Strategy for Primary Podocytopathies

Role: collaborator

NCT06869135Recruiting

Saliva and Extracellular Vesicles for Neurodegenerative Diseases

Role: collaborator

NCT06337955Active Not Recruiting

Non Primary HCMV Infection: Natural History and Immune Response

Role: collaborator

NCT05730023Not ApplicableRecruiting

A Multimodal Approach for Clinical Diagnosis and Treatment of Primary Progressive Aphasia, MAINSTREAM ID:3430931

Role: collaborator

NCT03973359Not ApplicableUnknown

Epidemiology and Prevention of Congenital HCMV in Immune Mothers. Congenital HCMV Infection Lombardy

Role: collaborator

All 5 trials loaded